Acute Porphyria Drugs

Monograph

R03CC12 - Bambuterol
Propably not porphyrinogenic
PNP

Rationale
Only limited hepatic load. Probably non-CYP metabolism. About 10 % of the absorbed dose gives rise to terbutaline ( i.e. 0.2-0.5 mg) "Rather low dose in large part not metabolised. No data pointing to CYP-interaction. One reference: authorised."
Chemical description
Long-acting adrenergic bronchodilator for systemic use (tabl. 10 - 20 mg, mixture 1mg/mL). used in bronchial asthma where glucocorticoide effect is insufficient. Prodrug to the beta-receptor agonist terbutaline. Only about 20 % of the dose is absorbed. About 1/3 is metabolized in the intestinal wall to intermediary metabolites. About 10% gives rise to terbutaline.
Similar drugs
Explore alternative drugs in similar therapeutic classes R03C / R03CC or go back.
References
Tradenames

Bambec Bambec Bambuterol
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙